NCT05736029 Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
| NCT ID | NCT05736029 |
| Status | Recruiting |
| Phase | — |
| Sponsor | OncoHost Ltd. |
| Condition | Non Small Cell Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2022-11-07 |
| Primary Completion | 2028-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2022-11-07 with a primary completion date of 2028-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.
Eligibility Criteria
Inclusion Criteria: * Provision of informed consent prior to any study-specific procedures. * Male or female aged at least 18 years. * ECOG PS - 0/1-2. Exclusion Criteria: * Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of treatment. * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.
Contact & Investigator
Ronan J Kelly, MD MBA
PRINCIPAL INVESTIGATOR
Chief of Oncology Baylor Scott & White Health System
Frequently Asked Questions
Who can join the NCT05736029 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Small Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05736029 currently recruiting?
Yes, NCT05736029 is actively recruiting participants. Contact the research team at galit@oncohost.com for enrollment information.
Where is the NCT05736029 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT05736029 clinical trial?
NCT05736029 is sponsored by OncoHost Ltd.. The principal investigator is Ronan J Kelly, MD MBA at Chief of Oncology Baylor Scott & White Health System. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.